Centene Corporation
CNC · What the business does, what can go wrong, and how options sellers approach it
What it does
Centene Corporation is a managed care company focused on government-sponsored health insurance. It runs health plans for people covered through Medicaid, Medicare (including Medicare Advantage and Part D prescription drug plans), and the individual insurance exchanges created under the Affordable Care Act. It also holds government contracts in other areas, such as military health programs.
How it makes money
Governments or members pay Centene a fixed amount per enrolled member, usually monthly. Centene then pays the medical claims for those members. The gap between the premiums it collects and the care costs and administrative expenses it pays is its profit. It also earns interest on the cash and investments it holds while claims are processed.
Why investors own it
- Exposure to government-funded healthcare, which tends to be less tied to the economic cycle than many industries.
- Scale in Medicaid, a program where states contract with a limited number of insurers.
- A business model that can grow as enrollment grows or as states and the federal government expand coverage.
What can go wrong
- Premium rates are often set in advance, so if medical costs rise faster than expected, margins shrink.
- Government policy changes, such as Medicaid eligibility rules, can shift enrollment quickly.
- Contracts with states can be lost or contested when they come up for renewal.
- Risk adjustment and rating methods can change what Centene is paid for sicker or healthier members.
- Heavy reliance on a few government payers concentrates risk.
What to watch
- Medical loss ratio (share of premiums spent on care)
- Membership by segment (Medicaid, Medicare, exchanges)
- State contract awards and renewals
- Medicaid redetermination and eligibility rule changes
- Risk adjustment payments and rate updates
- Medical cost trends, such as utilization and drug costs
- Management guidance versus actual results
Options income angle
Options on CNC are generally liquid, with active listings across many strikes and expirations, though the busiest trading is usually in near-term contracts. Implied volatility tends to rise around quarterly earnings, government rate announcements, and policy news affecting Medicaid, Medicare, or the exchanges. Changes in medical cost trends can also move it.
One caution for someone selling premium: managed care stocks can gap sharply when a company revises its cost outlook or policy surprises hit. A short call can cap gains in a sharp rally, and a short put can lead to owning shares after a steep drop. Premium collected may not offset a large move.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Centene's total revenues grew 19% to $194.8 billion in 2025, but medical costs grew faster. The health benefits ratio (HBR, medical costs as a percentage of premium revenue) rose to 91.9% from 88.3%. A non-cash goodwill impairment (a write-down of value recorded in past acquisitions) of $6.7 billion drove a GAAP diluted loss per share of $(13.53). Adjusted diluted EPS was $2.08, compared with $7.17 in 2024.
How the business did
- Revenue growth came from Medicare prescription drug plan (PDP) premium yield and membership, Marketplace growth and Medicaid rate increases. Segment revenues rose 9% in Medicaid, 62% in Medicare and 25% in Commercial.
- The higher HBR reflected lower Marketplace risk adjustment revenue, higher Marketplace medical costs, PDP program changes under the Inflation Reduction Act, and Medicaid costs in behavioral health, home health and high-cost drugs. Commercial gross margin fell $2.6 billion and Medicaid gross margin fell $556 million, while Medicare gross margin rose $388 million.
- Management flagged total impairment charges of $7.3 billion, including $513 million tied to a pending sale of the remaining Magellan Health businesses.
- Operating cash flow was $5.1 billion, compared with $154 million in 2024, helped by improved pharmacy rebate timing. The company repurchased 6.7 million shares for $400 million, with $1.8 billion remaining on the authorization.
- The SG&A expense ratio (administrative costs as a share of revenue) improved to 7.4% from 8.5%.
Risks specific to this company
- Medicaid cost lag: State rates are set from historical data, so rate increases can trail rising costs. The filing says rate adjustments may be delayed or insufficient to offset higher acuity (sicker members).
- Marketplace shrinkage and sicker members: Enhanced premium tax credits (federal subsidies for Marketplace premiums) expired on December 31, 2025. The company expects that, together with the Final Rule and the OBBBA (the 2025 federal budget law), this will reduce 2026 Marketplace membership and raise morbidity. Late in the second quarter of 2025 it also cut its expected risk adjustment revenue sharply.
- Contract losses and protests: The company is protesting the Texas and Georgia Medicaid reprocurements, where it was not a successful bidder. Its Florida Children's Medical Services contract is scheduled to conclude at the end of September 2026.
- Medicare Part D exposure: Federal reinsurance fell from 80% to 20% under the IRA, raising the company's share of drug costs. A $4.0 billion receivable from CMS for the 2025 plan year is expected to be paid within a year, and delays would hurt cash flow.
- Medicare audits and ratings: CMS plans to accelerate and expand risk adjustment data validation audits, which could force premium refunds. About 60% of Medicare Advantage members are in contracts rated 3.5 stars or better.
- Debt: Consolidated indebtedness was $17.4 billion. The debt-to-capital ratio was 46.5%, against a credit agreement maximum of 0.6 to 1.0, and the ratio rose because the impairment reduced equity.
What management is watching
- 2026 Marketplace pricing: Corrective pricing actions were taken for 2026 in states covering 95% of Marketplace membership, after rates were refiled for a higher expected baseline of illness.
- Regulatory timeline: OBBBA Medicaid work requirements and more frequent eligibility checks largely begin in 2027. Provider tax and state directed payment changes begin in 2028. Integrated D-SNP (dual-eligible plan) requirements begin in 2030 with certain restrictions in 2027, which management sees as a long-term growth opportunity.
- 2026 cash plans: Management expects net dividends of approximately $1.2 billion from regulated subsidiaries and capital expenditures of approximately $800 million.
- Balance sheet moves: A February 13, 2026 receivable purchase agreement allows the company to sell its 2025 Part D receivable. The senior note repurchase program has $1.5 billion available after a $1.0 billion increase.
- Measures pointed to: HBR and the SG&A expense ratio are the two key operating ratios, alongside adjusted diluted EPS and the debt-to-capital ratio.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Centene reported a GAAP diluted loss per share of $(0.14) for the third quarter of 2026, while adjusted diluted earnings per share (EPS, which strips out items such as severance and acquired-asset amortization) were $0.58. Revenue grew and the health benefits ratio held flat, but membership fell and the 2027 Medicare Advantage Star Ratings (CMS quality scores) came in lower.
How the business did
- Revenue and profit: Total revenues were $50.6 billion, up 2%, helped by state pass-through payments and rate increases, and partly offset by lower Marketplace and Medicaid membership. Managed care membership was 25.7 million, a decrease of 2.3 million members, or (8)%. For nine months, diluted EPS was $5.15 versus $(11.29), and the 2025 period carried a goodwill impairment.
- Medical costs: The health benefits ratio (HBR, medical costs as a share of premium revenue) was 92.7%, unchanged from a year earlier. A lower Marketplace HBR offset the 2025 benefit from a premium deficiency reserve release. For nine months it was 89.9% versus 91.1%.
- Segments: Medicare revenues rose 20% to $11,263 million on stand-alone drug plan (PDP) growth. Commercial revenues fell (21)% to $8,700 million as Marketplace membership shrank. Medicaid revenues rose 6% to $29,581 million.
- Costs: The SG&A expense ratio was 7.2% versus 7.0%. The adjusted ratio improved to 6.5%. The company recorded $276 million of severance costs from enterprise optimization and contract exits.
- Cash and capital: Operating cash flows used cash of $3.7 billion in the quarter because of the timing of pass-through payments. For nine months, operations provided $4,287 million. The company repurchased $1.8 billion of senior notes in that period, made no stock repurchases in the quarter, and reported a debt-to-capital ratio of 41.1% versus 46.5% at December 31, 2025.
What management is watching
- Medicare quality ratings: In October 2026, approximately 42% of Medicare Advantage members were in plans rated 3.5 stars or higher, versus approximately 60% the prior year. These ratings will be reflected in 2028 plan year revenues.
- Medicaid and Commercial changes: California moves its Unsatisfactory Immigration Status population to fee-for-service on January 1, 2027, affecting approximately 175,000 Health Net members. The company is also transitioning out of certain Hawaii contracts, did not keep the Florida Children's Medical Services contract, and is protesting awards in Georgia and Texas. Health Net will discontinue commercial group offerings in 2027.
- Rest of 2026: Management expects about $200 million of additional capital spending and net dividends of approximately $20 million from insurance subsidiaries. It anticipates the CMS settlement of 2025 Part D risk-sharing receivables in the fourth quarter of 2026. In October 2026 it repurchased the remaining $569 million of Senior Notes due 2027.
- Measures cited: The company points to the HBR, the SG&A expense ratio and its adjusted version, adjusted EPS, and the debt-to-capital ratio.
Follow CNC in Kortex
The Kortex app shows CNC's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.